[Synergetic activation of the nucleus accumbens nirtergic system by dopamine D1 and D2 receptor agonists].
In Sprague-Dawley rats by means in vivo microdialysis combined with HPLC analysis in was shown that an infusion into the medial n. accumbens of the dopamine D1 receptor agonist SKF-38393 (100 microM) caused a rise of extracellular levels of citrulline (an NO co-product) in this brain area (the average 139 +/- 3%), which was prevented by intraacumbal infusion of 0.5 mM 7-nitroindazole, a neuronal NO-synthase inhibitor. The intraaccumbal infusion of dopamine D2 receptor agonist quinelorane (100, 500, 1000 microM) did not affect the extracellular citrulline level in this brain area. Combined infusions into the medial nucleus accumbens of SKF-38393 (100 microM) and quinelorane (100 microM) produced a significant rise in citrulline extracellular levels (the average 243 +/- 14%) which was prevented by intraacumbal infusion of 0.5 mM 7-nitroindazole. The data obtained indicate for the first time that the nitregic system of the medial nucleus accumbens is under synergetic regulation of dopamine D1 and D2 receptors.
N B
NB
Saul'skaia
E A
EA
Terekhova
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000008:administration & dosage; D000818:Animals; D002956:Citrulline / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000008:administration & dosage; D065127:Dopamine D2 Receptor Antagonists; D004357:Drug Synergism; D007191:Indazoles / Q000008:administration & dosage; D017551:Microdialysis; D009474:Neurons / Q000187:drug effects; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009714:Nucleus Accumbens / Q000187:drug effects; D011804:Quinolines / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism
D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D007191:Indazoles; D011804:Quinolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D002956:Citrulline; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D019001:Nitric Oxide Synthase; C080122:7-nitroindazole; D004298:Dopamine; C047726:quinelorane